feed,title,long_url,short_url
Investors,Neurogene — Down 36% — Extends Losses After Side Effect Derails Its Rett Syndrome Drug,https://www.investors.com/news/technology/neurogene-stock-rett-rundrome-treatment-side-effect/,https://da.gd/R8Hkd
